Drug intelligence / Profile preview

AL-59412C

Development stage: Discontinued
Lead developer: Alcon
Modality: Small Molecules
Administration: Intravitreal

Overview

AL-59412C is an investigational drug that was initially developed by Alcon for the treatment of eye diseases, specifically open-angle glaucoma and ocular hypertension. The drug was studied for its ability to lower intraocular pressure when administered via intravitreal injection. Its mechanism of action has not been publicly detailed, and development has been discontinued[1][2][4].

Beyond the preview

Go deeper on AL-59412C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AL-59412C.

Explore the full profile